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Abstract
Background: Colorectal peritoneal carcinomatosis (CRPC) is a common form of systemic metastasis of intra-
abdominal cancers. Intraperitoneal chemotherapy is a preferable option for colorectal cancer. Here we reported
that a new system, 5-FU-loaded hydrogel system, can improve the therapeutic effects of intraperitoneal
chemotherapy.
Methods: A biodegradable PEG-PCL-PEG (PECE) triblock copolymer was successfully synthesized. The
biodegradable and temperature sensitive hydrogel was developed to load 5-FU. Methylene blue-loaded hydrogel
were also developed for visible observation of the drug release. The effects and toxicity of the 5-FU-hydrogel
system were evaluated in a murine CRPC model.
Results: The hydrogel system is an injectable flowing solution at ambient temperature and forms a non-flowing
gel depot at physiological temperature. 5-FU-hydrogel was subsequently injected into abdominal cavity in mice
with CT26 cancer cells peritoneal dissemination. The results showed that the hydrogel delivery system prolonged
the release of methylene blue; the 5-FU-hydrogel significantly inhibited the peritoneal dissemination and growth of
CT26 cells. Furthermore, intraperitoneal administration of the 5-FU-hydrogel was well tolerated and showed less
hematologic toxicity.
Conclusions: Our data indicate that the 5-FU-hydrogel system can be considered as a new strategy for peritoneal
carcinomatosis, and the hydrogel may provide a potential delivery system to load different chemotherapeutic
drugs for peritoneal carcinomatosis of cancers.
Background
Peritoneal carcinomatosis (PC) is one of the most com-
mon causes of incurability of intra-abdominal cancers,
among which colorectal peritoneal carcinomatosis
(CRPC) is a result of transcoelomic invasion by the pri-
mary cancer or intraperitoneal seeding during surgical
manipulation. Approximately 8% of patients have iso-
lated peritoneal seeding at the time of primary surgery,
and 25% of patients with recurrence have disease con-
fined to the peritoneal cavity [1,2]. Neither systemic che-
motherapy nor intraperitoneal chemotherapy alone had
any significant impact on survival [3]. The current goal
of treatment for most abdominal/peritoneal metastases
is palliative, rather than curative. It is imminent to
sought new strategies to improve the therapeutic effects
of intraperitoneal chemotherapy. Intraperitoneal infusion
of 5-fluorouracil (5-FU) is frequently used for PC in
patients with gastrointestinal malignancies and show
positive results [3]. As an antimetabolite drug, 5-FU can
incorporates into the DNA causing chain termination.
To obtain maximal therapeutic effects, the prolonged
and continuous administration is required.
Over the past decades, stimuli-sensitive polymers have
attracted much attention due to their great biodegrad-
ability, biocompatibility, and responsiveness to the phy-
sical-chemical stimulus, such as temperature, pH and
electrolyte composition [4-6], among which thermosen-
sitive hydrogel has been extensively studied for its
potential biomedical applications, including in situ gel-
forming controlled drug delivery, cell encapsulation, and
tissue repair [7-9]. Since a series of block copolymers
consisting of PEG and PCL was first prepared, these tri-
block copolymers have been widely studied [10-12]. In
our previous contribution, we have successfully prepared
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a series of thermosensitive hydrogels based on PECE
copolymer [13,14], which are injectable flowing solutions
at low temperature and undergo sol-gel transition at
around body temperature. Besides, intrapleural, intraper-
itoneal and subcutaneous administration of PECE
hydrogel were proved to be safe in BALB/c mice in vivo
by acute toxicity test [15]. Therefore, this work is very
important for the further application of PECE hydrogel
as an injectable in situ gel-forming controlled drug
delivery system.
In this study, we developed a 5-FU-loaded PECE
hydrogel system (5-FU-hydrogel). The therapeutic
effects of this system were evaluated in a murine CRCP
model. The results presented here are positive and sug-
gestive for a promising clinical application.
Methods
Synthesis and characterization of PECE copolymer
"-Caprolactone ("-CL, Alfa Aesar, USA), poly(ethylene
glycol) methyl ether (MPEG, Mn = 550, Aldrich, USA),
stannous octoate (Sn(Oct)2, Sigma, USA) and hexam-
ethylene diisocyanate (HMDI, Aldrich, USA) were used
without any further purification. All the materials used
in this article were analytic reagent (AR) grade, and
used as received.
PECE copolymer was synthesized as described in our
previous works. Briefly, PEG-PCL diblock copolymer
was prepared by ring-opening copolymerization of "-CL
initiated by MPEG using stannous octoate as catalyst;
PECE triblock copolymer was synthesized by coupling
PEG-PCL diblock copolymer using HMDI as coupling
agent.
The obtained PECE triblock copolymer was first dis-
solved in AR grade dichloromethane, and reprecipitated
from filtrate using AR grade petroleum ether. Then the
mixture was filtered and vacuum dried to constant
weight at room temperature. The purified PECE copoly-
mers were kept in desiccators before further use. The
copolymer was denoted as PEG-PCL-PEG (Y-X-Y)
where × and Y represented the number average molecu-
lar weight (Mn) of PCL and PEG block respectively.
Fourier transforms infrared spectroscopy (FTIR,
200SXV Infrared Spectrophotometer, Nicolet, USA),
nuclear magnetic resonance analysis (1H-NMR, Varian
400 spectrometer, Varian, USA), and gel permeation
chromatography (GPC, Agilent 110 HPLC, USA) were
used to characterize the chemical structure and macro-
molecular weight of prepared PECE copolymer.
Preparation of blank or 5-FU loaded PECE hydrogel
The PECE copolymer was dissolved in normal saline
(n.s.) solution at designated temperature at the concen-
tration of 25wt% to form blank PECE hydrogel, and
then the blank PECE hydrogel was kept at 4°C before
use. 5-FU loaded PECE hydrogel was prepared by direct
dissolution method. Calculated amount of 5-FU was
added into PECE hydrogel (25wt%) at 4°C (sol state) to
form injectable homogeneous sol. The prepared 5-FU
loaded PECE hydrogel was kept at 4°C before use.
In vitro drug release profile of PECE hydrogel
5-FU was used as a model drug to determine the
in vitro drug release behavior from PECE hydrogel.
Phosphate buffer solution (PBS, pH = 7.4) was used as
release medium. A membraneless model was introduced
to assay the release behavior of PECE hydrogel in vitro.
In detail, 200 μl of 5-FU loaded PECE hydrogel (25wt%
of hydrogel containing 0.5 or 1 mg of 5-FU respectively)
were placed into 4 ml-EP tubes and allowed to gel in an
incubator at 37°C for 12 h. Then, the gels were
immersed in 1 ml of PBS (pH = 7.4) and were shaken at
100 rpm at 37°C. At specific time, all the release media
were removed and replaced by pre-warmed fresh release
media. After centrifugation at 13000 rpm for 10 min,
the supernatant of the removed release media were col-
lected and stored at -20°C until analysis. The concentra-
tion of 5-FU in the collected supernatants were
determined by UV spectrophotometer at 286 nm. All
the release study experiments were repeated three times.
All data are expressed as the mean ± S.D.
Cell and animals
Colon cancer cell line CT26 were obtained from ATCC
(American Type Culture Collection) (Manassas, VA),
and cultured in RPMI-1640 (Gibco), supplemented with
10% fetal bovine serum (FBS) plus ampicillin and strep-
tomycin routinely in a 5% CO2 incubator at 37°C.
Female Balb/c mice (6-8 weeks old) were purchased
from the Laboratory Animal Center of Sichuan Univer-
sity. Animal experiments were approved by the Institu-
tional Animal Care and Treatment Committee of
Sichuan University (Chengdu, China).
Observation of the release of methylene blue in
methylene blue-loaded hydrogel in mice
Methylene blue-loaded hydrogel was prepared with the
same way as 5-FU-hydrogel. The methylene blue-loaded
hydrogel with a form of solution was infused into mur-
ine abdominal cavity. The changes of methylene blue
were observed.
RCPC Mice model and treat plan
RCPC mice model was established and subsequently
treated. Briefly, 2 × 105 CT26 cells were injected into
murine abdominal cavity. Five day later, these Balb/c
mice were divided four groups (n = 10) received n.s.,
hydrogel, 5-FU (25 mg/kg) and 5-FU-hydrogel, respec-
tively. All of the treatments were performed once per
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week for two weeks. Mice were sacrificed on 20th day,
the size and numbers of tumor nodes were measured.
Evaluation of systemic toxicity
To investigate potential side effects or toxicity on mice
during the treatment, they were observed continuously
for relevant indexes such as weight loss, diarrhea, anor-
exia, skin ulceration and toxic deaths. The tissues of
heart, liver, spleen, lung, kidney and brain were stained
with H&E. The blood was obtained from tail vein once
per week to detect the hematologic toxicity.
Results
Synthesis and characterization of PECE copolymer
The PEG-PCL diblock copolymer was prepared by ring-
opening copolymerization of "-CL initiated by MPEG
using stannous octoate as catalyst, and biodegradable
PECE triblock copolymer was synthesized from PEG-
PCL diblock copolymer using HMDI as coupling agent.
FTIR, 1H-NMR and GPC were used to characterize the
chemical structure of PECE copolymer.
The Mn and PEG/PCL block ratio of PECE triblock
copolymer calculated from 1H-NMR spectra was 3408
and 960/2448 respectively. Molecular weight and poly-
dispersity (PDI, Mw/Mn) of PECE triblock copolymer
determined by GPC were 4391 and 1.30 respectively.
FTIR, 1H-NMR, and GPC results indicated that the
PECE triblock copolymer designed by controlling the
feed composition were prepared successfully.
Temperature-dependent sol-gel-sol transition behavior
As shown in Figure 1A, the PECE copolymer displayed a
special temperature-dependent sol-gel-sol transition in
n.s. When the concentration was above corresponding
critical gelation concentration (CGC), the aqueous solu-
tion of PECE copolymer undergo a sol-gel-sol transition
as the temperature increases. In Figure 1B, at low tem-
perature, the hydrogel is an injectable flowing sol, and
forms a non-flowing gel in body temperature.
In vitro drug release profile
In vitro release behavior of 5-FU from PECE hydrogel
was studied, and the results were shown in Figure 2. 5-
FU could be released from 5-FU-hydrogel in a sustained
period. The initial drug loading amount had great effect
on 5-FU release profile. With lower initial drug loading
amount (0.5 mg), 5-FU released faster and reached
higher cumulative release rate (95.3%) compared to
higher initial drug loading hydrogel (84.6%). In PECE
hydrogel containing 0.5 mg 5-FU, an initial burst release
of 26.2% of loaded 5-FU occurred in the first one hour,
followed by releasing of 82.9% in one day, whereas, with
twice amount of loaded 5-FU, the cumulative release
rate of one hour and one day were 19.8% and 65.8%
respectively.
The hydrogel prolongs the release of methylene blue and
enhances the permeability of peritoneum
To observe the release or uptake process of drug loaded in
hydrogel in a way of intraperitoneal administration. The
methylene blue-loaded hydrogel was infused into murine
abdominal cavity for mimic the condition. The release of
methylene blue was significantly delayed (Figure 3). Inter-
estingly, methylene blue was observed in bladder lasting
more than 48 hours. These findings suggest that the
hydrogel system not only act as a sustained drug delivery
Figure 1 Sol-gel-sol phase transition of PECE hydrogel. A: Sol-gel-sol phase transition diagram. When the concentration was above
corresponding critical gel concentration (CGC), the aqueous solution of PECE copolymer undergo a sol-gel-sol transition as the temperature
increases.B: Photograph of PECE hydrogel at 10°C (right) and at 37°C (left). At low temperature, the hydrogel is an injectable flowing sol, and
forms a non-flowing gel in body temperature.
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system, but also improve the permeability of methylene
blue into abdominal tissue, further into blood.
The 5-FU-hydrogel significantly inhibits the peritoneal
dissemination and growth of colorectal cancer
CRPC mice model was established and used to evaluate
the therapeutic effects. To observe dose-dependent
effects, we first performed a dose gradient assay in vivo.
CRPC mice were divided four groups (n = 5) treated
with 5-FU-hydrogel loaded different doses of 5-FU (25
mg/kg, 50 mg/kg, 100 mg/kg and 250 mg/kg). However,
the inhibitory effects were not significantly improved
when the dose of 5-FU-hydrogel increased more than 25
mg/kg (data not shown). Therefore, the dose of 5-FU at
25 mg/kg was selected for further study.
To investigate the therapeutic effects of 5-FU-hydro-
gel, forty CPRC mice were divided four groups treated
with n.s, hydrogel alone, 5-FU alone and 5-FU-hydrogel.
The results showed that the tumor node numbers from
5-FU-hydrogel-treated group were significantly less than
that from other groups (table 1). Furthermore, the size
of tumor nodes was significantly smaller in comparison
to other groups (Figure 4). Subsequently, the increased
tumor free rate and survival rate were also observed in
5-FU-hydrogel-treated group. This finding indicates 5-
FU-hydrogel not only impair tumor dissemination, but
also inhibits growth of implanted tumor.
Systemic toxicity analyses
In this study, we also investigated the cytotoxicity of the
treatment. Body weights of mice were monitored every
five days. No obvious signs of adverse results were
observed in body weight, behavior or feeding. The
serum ALT (alanine aminotransferase) and AST (aspar-
tate aminotransferase) levels were among normal range,
as well as creatine levels. In addition, hematoxylin and
eosin staining sections of liver, kidney, and lung were
observed under microscope. No organ hemorrhage was
found (data not shown). However, the hematologic toxi-
city showed significant difference. On the 14th day, the
number of white cells from 5-FU-hydrogel-treated mice
was higher than that from the 5-FU-treated group (Fig-
ure 5). The data indicate hydrogel system attenuate the
hematologic toxicity of 5-FU in spite of the increased
permeability.
Discussion
The current therapy recommended by guideline of
NCCN for CRPC is palliative. Nevertheless, the treat-
ment of disseminated carcinomatosis with cytoreductive
surgery (ie, peritoneal stripping surgery) and periopera-
tive hyperthermic intraperitoneal chemotherapy has
been considered as a new therapeutic concept to cure
CRPC [16,17]. Importantly, intraperitoneal chemother-
apy for CRPC is recommendable and should be immedi-
ately performed along with peritoneal surgery so that
residual tumor cells do not get trapped in the post-
operative fibrin adhesions [18]. In this study, we
reported that the hydrogel system, a biodegradable poly
(ethylene glycol)-poly ("-caprolactone)-poly (ethylene
glycol) (PEG-PCL-PEG, PECE) triblock copolymer, can
be used as a delivery vector to load chemotherapeutic
drugs for intraperitoneal infusion chemotherapy. Here,
methylene blue was used to mimic the release and
uptake of drugs; 5-FU was used as a model drug.
Although the methylene blue and 5-FU may be released
from the hydrogels at different rates, the results strongly
support that PECE hydrogel can endue the delayed-
release properties and increased permeability of drugs.
For intraperitoneal chemotherapy, prolonged stay and
increased permeability of drugs are helpful for better
disease control. In fact, the 5-Fu-loaded-hydrogel system
did show significantly increased therapeutic effects for
CRPC.
In recent years, biodegradable thermosensitive hydro-
gels have been wildly investigated as controlled drug
delivery system, in which pluronic F127 and PEG-PLGA
copolymer were the most extensively studied ones
[19,20]. Pluronic F127 is a commercial thermosensitive
hydrogel, which has been widely used as emulsifiers,
wetting agents, and solubilizers [20,21]. However, the
critical micelle concentration (CMC) of Pluronic F127 is
very high due to weak hydrophobicity of PPG block.
Pluronic F127 forms a fast-eroding gel and can not per-
sist longer than a few hours in vivo. Furthermore,
Figure 2 In vitro release behavior of 5-FU from PECE hydrogel
(25wt%). Error bars represent the standard deviation (n = 3). 5-FU
could be released from PECE hydrogel in a sustained period. The
initial drug loading amount had great effect on 5-FU release profile.
With lower initial drug loading amount (black square), 5-FU released
faster and reached higher cumulative release rate compared to
higher initial drug loading hydrogel (black circle).
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Figure 3 The hydrogel system delayed release and increased uptake of methylene blue. Mice were intraperitoneally injected methylene
blue-hydrogel and then sacrificed at 2 h, 8 h, 24 h, 48 and 72 h to observe the release and increased uptake of methylene blue. The
hydrogelization of methylene blue resulted in delayed release and increased uptake until 48 h (white short arrows), while methylene blue alone
were discharged at about 8 h. The delayed release of methylene blue also observed in bladder (black long arrows).
Table 1 The enhanced anti-tumor effects of 5-FU-hydrogel
Groups Mean number of tumor nodes Tumor-free rate % Survival rate %
n.s 20.2 ± 10.08 0 62.5
Hydrogel 23.67 ± 6.98 0 75
5-FU 11.6 ± 3.8 0 62.5
5-FU + Hydrogel 5.3 ± 4.04* 42.5** 100*
*,**Indicates p < 0.05 and p < 0.01, respectively
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Figure 4 5-FU-hydrogel system effectively inhibited the peritoneal dissemination and growth of colorectal cancer. The decreased tumor
nodes and tumor size were observed followed by intraperitoneal infusion of 5-FU-Hydrogel.
Figure 5 Lack of toxicity-dependent weight loss in mice pretreated with 5-FU-hydrogel. Body weights of tumor-bearing mice were
plotted at 2-d intervals and the curve of the HNP1 group paralleled very closely to that of the control groups with no significant differences
among them (A, P > 0.05). Mean ± SD. On the 14th day, the number (mean value) of white blood cells from 5-FU-hydrogel-treated mice was
higher than that from the 5-FU-treated group.
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Pluronic was found to induce the toxic enhancement of
plasma cholesterol and triglycerol because it was non-
biodegradable and could be accumulated in the body
[22,23]. Thus, the wider application of Pluronic in many
biomedical fields was greatly restricted.
In our work, we have synthesized a biodegradable
Pluronic analog. Polycaprolactone (PCL) was used
instead of PPG to synthesize PECE copolymer, and the
formed hydrogel could persist approximately 5 days in
vivo by intraperitoneal administration. Incorporation of
biodegradable and strong hydrophobic block into Pluro-
nic copolymer backbone will result in distinct decrease
in macromolecular weight after degradation, easier elim-
ination from the body, and evident decrease in CMC.
Unlike PEG-PLGA hydrogel [19], the PECE hydrogel
forms a soft gel at body temperature and could not hurt
any organs in intraperitoneal cavity, which is suitable for
intraperitoneal administration.
Currently, the drugs-combined intraperitoneal che-
motherapy (ie. 5-FU and mitomycin-C) and intraperito-
neal chemohyperthermia (IPCH) are recommended
treatment modalities owing to improved therapeutic
effects on PC [16,24,25]. Furthermore, the combination of
IPCH and cytoreduction has shown curable potential to
PC in some clinical trials [24,26,27]. However, recurrence
is still a frequent event after optimal cytoreduction and
IPCH for CRPC [28], and the modalities are still investiga-
tional and do not endorse extended applications outside of
a clinical trial. Enhancing the effects of intraperitoneal
infusion chemotherapy should be responsible for improve
curable potential of the combined modalities to PC.
In the 5-FU-Hydrogel system, temperature sensitivity
of Hydrogel is very important. At low temperature (<32°
C), the fluidity of the system enable the easy infusion
and extensive distribution. The murine body tempera-
ture is about 37°C. When the system was infused intra-
peritoneally, the formed gel phase guaranteed the
delayed drug release, and increased drug uptake.
Conclusions
This study demonstrates that the biodegradable PECE
hydrogel is a promising in situ gel-forming controlled
drug delivery system. Aqueous solution of PECE copoly-
mers undergoes sol-gel-sol transition as temperature
increases. In vitro drug release behavior indicated that
PECE hydrogel could provide a sustained release profile.
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